FBI Enters CRADA with SeqLL to Explore New Forensic Capabilities
The U.S. Department of Justice’s Federal Bureau of Investigation (FBI) has entered into a cooperative research and development agreement (CRADA) with SeqLL Inc., a technology company providing life sciences instrumentation and research services. Under this CRADA, SeqLL and the FBI Laboratory Division (FBI LD) will seek to evaluate and determine the forensic capabilities of direct RNA sequencing using the SeqLL True Single Molecule Sequencing (tSMS®) platform.
The FBI LD and SeqLL will collaborate with a goal of producing an assay for forensic body fluid identification, without compromising traditional STR or DNA sequence analysis. This agreement is among the first times the FBI is utilizing the CRADA mechanism to further develop laboratory capabilities.
Photo caption: The outside of the FBI Laboratory in Quantico, Virginia, in 2019. Learn more about science and technology work at the FBI Lab.